Healthcare Services company Thyrocare Technologies announced Q3FY26 results Consolidated revenue registered a 18% YoY growth, driven primarily by a 20% increase in the Pathology segment. In the Pathology business, franchise revenue grew by 12% YoY, while partnership revenue including pharmeasy business recorded a robust 39% YoY growth. Thyrocare, India’s largest diagnostic test volume processor, processed 49.6 million tests in Q3FY26, marking a strong 22% YoY growth and reinforcing its leadership position in the diagnostics industry. Consolidated EBITDA grew by 38% YoY, and Profit After Tax (PAT) grew by 47% YoY to Rs 27.91 crore after considering exceptional items relating to non-recurring labour code & bonus issue impact. Achieved Six Sigma quality standards (defined as 3.4 CPMT), reducing complaints per million tests to 3.2 (down 43% YoY) with ATAT at 3.28 hours - India's first diagnostic chain to hit this benchmark. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India.” Result PDF
Healthcare Services company Thyrocare Technologies announced Q2FY26 results Consolidated revenue of Rs 216.53 crore, registering a strong 22% YoY growth. EBITDA rose sharply by 49% YoY to Rs 75.36 crore. EBITDA margin of 33% for Q2FY26. Profit After Tax surged 82% YoY to Rs 47.90 crore. PAT Margin: 22% for Q2FY26. Board of Directors has declared an interim dividend of Rs 7 per equity share (of Rs 10 face value each, pre-bonus) with 24-October-2025 as the record date, and approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approval. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and valuedriven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India” Alok Kumar, Jagnani Group CFO, said: “We are delighted with Thyrocare’s strong Q2FY26 performance, which reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey”. Result PDF
Healthcare Services company Thyrocare Technologies announced Q1FY26 results Q1FY26 Financial Highlights: Revenue from operations: Rs 193.03 crore compared to Rs 156.91 crore during Q1FY25, change 23%. EBITDA: Rs 57.46 crore compared to Rs 42.01 crore during Q1FY25, change 37% EBITDA Margin: 30% for Q1FY26. PAT: Rs 38.06 crore compared to Rs 23.47 crore during Q1FY25, change 62%. PAT Margin: 20% for Q1FY26. Business Highlights: Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY. Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase. Opened New Labs in Bhagalpur, Kashmir and Roorkee. Result PDF